Dave Miller, PhD, explains how early formulation planning, novel platforms, and tailored approaches secure long-term protection against generics.

Based on an analysis done by the European Medicines Agency on the feasibility of alternatives, the European Commission ...

Dave Miller, PhD, discusses how shifting drug manufacturing to domestic CDMOs can improve quality, reduce rework, and enhance ...

For the first target addressed in the partnership, the two companies reported the successful delivery of AI-designed, ...

The company’s expanded label for Avtozma (tocilizumab-anoh) now includes the treatment of cytokine release syndrome, aligning ...

The company’s commitment to its North Chicago, Ill. plant is part of a previously announced $10 billion capital investment ...

The new targeted pipeline will advance Nxera’s oral GLP-1 agonists, novel GPCR targets, and structure-based drug design to ...

The scaled adoption of cell and gene therapies demands a new era of agile, precise, and efficient quality control methods.

Experts from LGM Pharma and Rockwell Automation share their thoughts on what makes tech transfer effective, where processes ...

The agency’s new program is designed to increase regulatory predictability and streamline review of domestic manufacturing ...

A new nuclear magnetic resonance method reveals real-time, coordinated changes in nanoemulsion drugs, improving noninvasive ...

Dave Miller, PhD, explains how environmental audits, waste reduction, and supply chain security are reshaping priorities in pharmaceutical manufacturing.